Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of SPH4336 plus endocrine therapy after progression on prior CDK4/6 inhibitor plus endocrine therapy in HR-positive, HER2-negative advanced or metastatic breast cancer
CTR20231256Phase 3Active
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SPH4336 in breast cancer, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Sep 2023; status: active.
02
Drugs
SPH4336
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20231256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231256.